Refractory clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin

Case Reports in Medicine

Volumn 2012, Issue , 2012, Pages

  Lao, Dominador ^a   Chiang, Tom ^b   Gomez, Eric ^c  

^a St Matthews School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Appalachian Regional Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CLOSTRIDIUM DIFFICILE TOXIN A; LACTIC ACID; METRONIDAZOLE; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEVER; HUMAN; LACTATE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; NAUSEA; PANCOLITIS; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84886718124     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2012/702910     Document Type: Article

References (18)

1. Freeman J., Bauer M. P., Baines S. D., Corver J., Fawley W. N., Goorhuis B., Kuijper E. J., Wilcox M. H., The changing epidemiology of Clostridium difficile infections Clinical Microbiology Reviews 2010 23 3 529 549
2. Gerding D. N., Johnson S., Management of Clostridium difficile infection: thinking inside and outside the box Clinical Infectious Diseases 2010 51 11 1306 1313
3. Vardakas K. Z., Polyzos K. A., Patouni K., Rafailidis P. I., Samonis G., Falagas M. E., Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence International Journal of Antimicrobial Agents 2012 40 1 1 8
4. Marchese A., Salerno A., Pesce A., Debbia E. A., Schito G. C., In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species Chemotherapy 2000 46 4 253 266 (Pubitemid 30428839)
5. DuPont H. L., Jiang Z. D., Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci Clinical Microbiology and Infection 2004 10 11 1009 1011
6. Gerding D. N., Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines Discovery Medicine 2012 13 68 75 83
7. Berman A. L., Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile -associated diarrhea Journal of Clinical Gastroenterology 2007 41 10 932 933 (Pubitemid 350307082)
8. Johnson S., Schriever C., Galang M., Kelly C. P., Gerding D. N., Interruption of recurrent Clostridium difficile -associated diarrhea episodes by serial therapy with vancomycin and rifaximin Clinical Infectious Diseases 2007 44 6 846 848 (Pubitemid 46365312)
9. El-Herte R. I., Baban T. A., Kanj S. S., Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature Scandinavian Journal of Infectious Diseases 2012 44 3 228 230
10. Hawser S. P., Activity of tigecycline against recent European clinical isolates of Clostridium difficile International Journal of Antimicrobial Agents 2010 35 1 97 98
11. Norén T., Alriksson I., kerlund T., Burman L. G., Unemo M., In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden Clinical Microbiology and Infection 2010 16 8 1104 1110
12. Baines S. D., Saxton K., Freeman J., Wilcox M. H., Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model Journal of Antimicrobial Chemotherapy 2006 58 5 1062 1065
13. Hecht D. W., Galang M. A., Sambol S. P., Osmolski J. R., Johnson S., Gerding D. N., In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004 Antimicrobial Agents and Chemotherapy 2007 51 8 2716 2719 (Pubitemid 47206204)
14. Jump R. L., Li Y., Pultz M. J., Kypriotakis G., Donskey C. J., Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production Antimicrobial Agents and Chemotherapy 2011 55 2 546 549
15. Herpers B. L., Vlaminckx B., Burkhardt O., Blom H., Biemond-Moeniralam H. S., Hornef M., Welte T., Kuijper E. J., Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection Clinical Infectious Diseases 2009 48 12 1732 1735
16. Cheong E. Y., Gottlieb T., Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis The Medical Journal of Australia 2011 194 7 374 375
17. Lu C. L., Liu C. Y., Liao C. H., Huang Y. T., Wang H. P., Hsueh P. R., Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole International Journal of Antimicrobial Agents 2010 35 3 311 312
18. Kopterides P., Papageorgiou C., Antoniadou A., Papadomichelakis E., Tsangaris I., Dimopoulou I., Armaganidis A., Failure of tigecycline to treat severe Clostridium difficile infection Anaesthesia and Intensive Care 2010 38 4 755 758